Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.Eli Lilly's (LLY +10.33%) obesity drug, Zepbound, generated sales of $13.5 billion in 2025. Its Type 2 diabetes drug Mounjaro, which is also marketed for treating obesity outside of the U.S., Canada, and Japan, raked in nearly $23 billion last year. Meanwhile, Novo Nordisk's (NVO 6.22%) obesity franchise made the Denmark-based drugmaker 82.3 billion Danish krone (roughly $13 billion). What was Pfizer's (PFE +4.08%) revenue in the obes ...